Tags : Pancreatic cancer

BioLineRx’s Motixafortide (BL-8040) Receives EC’s ODD to Treat Pancreatic Cancer

Shots: The EC has granted ODD to Motixafortide (BL-8040) for the treatment of pancreatic cancer following the positive COMP’s opinion The ODD designation is based on initial data of ongoing P-IIa COMBAT/KEYNOTE-202 study assessing the combination of BL-8040 + Keytruda (pembrolizumab) + CT in patients with m-pancreatic cancer Motixafortide is a selective inhibitor of the […]Read More

InxMed Signs a Clinical Trial Collaboration with Merck & Co

Shots: InxMed to sponsor the trial while Merck & Co (MSD outside the United States and Canada) will provide pembrolizumab for evaluation in the trial   The focus of the collaboration is to evaluate the combination of InxMed’s IN10018 plus Merck’s pembrolizumab in patients with pancreatic cancer IN10018 (formerly BI853520) is an investigational selective ATP-competitive […]Read More

OBI Pharma’s OBI-999 Receives the US FDA’s Orphan Drug Designation

Shots: OBI Pharma has initiated the enrollment of P-I/II study at the University of Texas M.D. Anderson Cancer Center to evaluate the therapy in patients with LA/m-solid tumors The objective of the study is to assess the safety & preliminary efficacy profile of OBI-999 in patients with pancreatic, gastric, colorectal and esophageal cancers OBI-999 is […]Read More